GlassScriptPhysician profile
Andrew M Wilhelm
NPI 1437237732
$51,023.02
in general payments reported to CMS, 2019-2025
39 companies · $18K in 2025
The $18K reported for 2025 was more than what 95% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29K · 2020: $398 · 2021: $827 · 2022: $1,179 · 2023: $1,134 · 2024: $1,296 · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16K · Food and Beverage: $3,689.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,334.68 |
| Food and Beverage | $3,688.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $27,106.56 | 2019 | |
| Genzyme Corporation | $8,661.51 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $8,395.89 | 2022-2025 | Dupixent |
| Glaxosmithkline, LLC. | $1,626.41 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Astrazeneca Pharmaceuticals LP | $721.40 | 2019-2025 | Airsupra, Fasenra, Breztri |
| Pfizer INC. | $719.11 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $610.25 | 2019-2025 | Ofev, Jascayd |
| Merck Sharp & Dohme LLC | $393.85 | 2019-2025 | Zerbaxa, Recarbrio, Winrevair |
| Actelion Pharmaceuticals US, INC. | $349.92 | 2020-2023 | Uptravi |
| Abbvie INC. | $251.85 | 2021-2025 | Avycaz, Teflaro |
| Insmed, INC. | $213.35 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $203.95 | 2020-2023 | Acthar |
| Intuitive Surgical, INC. | $191.13 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $179.72 | 2019-2024 | |
| United Therapeutics Corporation | $166.99 | 2019-2021 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $163.71 | 2019 | |
| Grifols USA, LLC | $148.24 | 2019-2025 | Prolastin-C Liquid |
| Astellas Pharma US INC | $116.20 | 2019-2021 | |
| Inari Medical, INC. | $93.23 | 2023-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Genentech USA, INC. | $88.10 | 2019-2021 | |
| Pulmonx Corporation | $72.04 | 2025 | Zephyr Endobronchial Valve, Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console |
| Ambu INC. | $70.59 | 2025 | |
| Allergan, INC. | $58.91 | 2019 | |
| La Jolla Pharmaceutical Company | $49.15 | 2019-2025 | Giapreza |
| Mylan Specialty L.P. | $49.11 | 2019-2024 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $40.64 | 2025 | Glassia |
| Janssen Pharmaceuticals, INC | $36.20 | 2023-2024 | Xarelto |
| Gilead Sciences, INC. | $34.12 | 2019 | |
| Verona Pharma, INC. | $33.46 | 2025 | Ohtuvayre |
| Philips North America LLC | $31.22 | 2020 | |
| Novartis Pharmaceuticals Corporation | $29.23 | 2019-2020 | |
| Mauna Kea Technologies, INC. | $26.64 | 2024 | |
| Ani Pharmaceuticals, INC. | $25.93 | 2025 | Purified Cortrophin Gel |
| Tetraphase Pharmaceuticals, INC. | $17.86 | 2020 | |
| Portola Pharmaceuticals, LLC | $17.52 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.69 | 2025 | Xifaxan |
| Vapotherm INC | $13.34 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Wilhelm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.